StocksMedium•13 November 2026•
1 min read
Tempest Therapeutics Beats Q3 EPS Estimates
Key Facts
1Tempest Therapeutics reported a GAAP EPS loss of $0.21, beating analyst estimates by $0.11.
Tempest Therapeutics reported a GAAP EPS loss of $0.21 for the third quarter, beating analyst estimates by $0.11. Seeking Alpha reported that the company's financial results for the fiscal period came in significantly better than the consensus analyst estimate.
Tempest Therapeutics ended the quarter with $0.9 million in cash and cash equivalents, compared to $7.7 million on December 31, 2025. TPST closed at $0.383 on November 12, 2026, with a daily trading range between $0.3701 and $0.3997.